Iqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the sale, the general counsel now owns 118,265 shares in the company, valued at approximately $1,808,271.85. This trade represents a 4.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Centessa Pharmaceuticals Stock Up 2.0 %

Shares of CNTA traded up $0.29 during mid-day trading on Friday, reaching $15.16. The company had a trading volume of 459,371 shares, compared to its average volume of 531,983. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -9.91 and a beta of 1.53. The firm has a 50-day moving average price of $16.90 and a 200 day moving average price of $14.54. Centessa Pharmaceuticals plc has a 52 week low of $7.38 and a 52 week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Ratings Changes

CNTA has been the topic of a number of research reports. Guggenheim lifted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 15th. B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price objective on the stock. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, TD Cowen initiated coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and an average target price of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in CNTA. First Light Asset Management LLC increased its holdings in shares of Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after purchasing an additional 1,778,515 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Centessa Pharmaceuticals by 438.0% during the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after buying an additional 1,625,000 shares during the last quarter. Janus Henderson Group PLC bought a new stake in Centessa Pharmaceuticals in the 3rd quarter worth about $20,698,000. Franklin Resources Inc. raised its position in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after buying an additional 1,145,823 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its stake in Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after acquiring an additional 987,997 shares during the period. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.